Inflammatory bowel disease new-onset during secukinumab therapy: real-world data from a tertiary center.
Rev Esp Enferm Dig
; 113(12): 858-859, 2021 Dec.
Article
in En
| MEDLINE
| ID: mdl-34696593
ABSTRACT
Secukinumab is a monoclonal antibody that inhibits interleukin-17A. It is currently prescribed for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis, which are immune-mediated diseases that show significant co-heritability with inflammatory bowel disease (IBD). Although this treatment appears to be well tolerated by patients, several cases of new-onset IBD after secukinumab have been reported during the last years.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Spondylitis, Ankylosing
/
Inflammatory Bowel Diseases
/
Arthritis, Psoriatic
Limits:
Humans
Language:
En
Journal:
Rev Esp Enferm Dig
Journal subject:
GASTROENTEROLOGIA
Year:
2021
Document type:
Article